REGENXBIO (RGNX) Stock Forecast, Price & News

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for REGENXBIO in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RGNX shares.
View RGNX analyst ratings or view top-rated stocks.

6 brokers have issued 1-year price objectives for REGENXBIO's shares. Their RGNX share price forecasts range from $14.00 to $61.00. On average, they predict the company's stock price to reach $40.00 in the next year. This suggests a possible upside of 132.2% from the stock's current price.
View analysts price targets for RGNX or view top-rated stocks among Wall Street analysts.

REGENXBIO's stock was trading at $22.68 on January 1st, 2023. Since then, RGNX stock has decreased by 24.0% and is now trading at $17.23.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023.
View our RGNX earnings forecast.

REGENXBIO Inc. (NASDAQ:RGNX) released its quarterly earnings results on Wednesday, May, 3rd. The biotechnology company reported ($1.53) earnings per share for the quarter, missing the consensus estimate of ($1.52) by $0.01. The biotechnology company had revenue of $19.10 million for the quarter, compared to the consensus estimate of $31.29 million. REGENXBIO had a negative net margin of 246.50% and a negative trailing twelve-month return on equity of 49.69%. The company's quarterly revenue was down 14.0% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.62) earnings per share.

ETFs with the largest weight of REGENXBIO (NASDAQ:RGNX) stock in their portfolio include Invesco Dynamic Biotechnology & Genome ETF (PBE), Global X Genomics & Biotechnology ETF (GNOM), WisdomTree BioRevolution Fund (WDNA), ETC 6 Meridian Small Cap Equity ETF (SIXS), Invesco S&P SmallCap 600 Pure Growth ETF (RZG), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Invesco S&P SmallCap Health Care ETF (PSCH) and Invesco Raymond James SB-1 Equity ETF (RYJ).

3 employees have rated REGENXBIO Chief Executive Officer Ken Mills on Glassdoor.com. Ken Mills has an approval rating of 68% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other REGENXBIO investors own include AbbVie (ABBV), Micron Technology (MU), NVIDIA (NVDA), Voyager Therapeutics (VYGR), Amarin (AMRN), CRISPR Therapeutics (CRSP), Pfizer (PFE), QUALCOMM (QCOM), Gilead Sciences (GILD) and Block (SQ).

REGENXBIO trades on the NASDAQ under the ticker symbol "RGNX."

REGENXBIO's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (18.50%), JPMorgan Chase & Co. (9.21%), State Street Corp (5.94%), Dimensional Fund Advisors LP (3.53%), Geode Capital Management LLC (1.75%) and First Manhattan CO. LLC. (1.03%). Insiders that own company stock include Allan M Fox, Curran Simpson, Kenneth T Mills, Kenneth T Mills, Patrick J Christmas, Steve Pakola, Vittal Vasista and WR Stephens, Iii 2012 Trust.
View institutional ownership trends.

Shares of RGNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RGNX stock can currently be purchased for approximately $17.23.

REGENXBIO (NASDAQ:RGNX) has a market capitalization of $748.99 million and generates $112.72 million in revenue each year. The biotechnology company earns $-280,320,000.00 in net income (profit) each year or ($6.24) on an earnings per share basis.

The company employs 372 workers across the globe.

REGENXBIO's mailing address is 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850. The official website for the company is www.regenxbio.com. The biotechnology company can be reached via phone at (240) 552-8181 or via email at ir@regenxbio.com.